A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
Sacituzumab govitecan in breast cancer
2021
Translational Breast Cancer Research
Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 receptor (HER2) on cancer cell surface. Approximately 15% of breast cancer (BC) patients were diagnosed with TNBC and had the worst prognosis among all subtypes of BC (1). Currently, chemotherapy remains to be the backbone for treatment of metastatic TNBC (mTNBC). However, standard chemotherapy is associated with low
doi:10.21037/tbcr-21-28
fatcat:acsvmhtcije7vftegtcrp5uw2q